Auteurs Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C
Genes & development May 2017
Focus on cutaneous and uveal melanoma specificities.Auteurs Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C
Genes & development May 2017
Focus on cutaneous and uveal melanoma specificities.Auteurs Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C
Genes & development May 2017
Focus on cutaneous and uveal melanoma specificities.Auteurs Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C
Genes & development May 2017
Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.Auteurs Bonet C, Luciani F, Ottavi JF, Leclerc J, Jouenne FM, Boncompagni M, Bille K, Hofman V, Bossis G, Marco de Donatis G, Strub T, Cheli Y, Ohanna M, Luciano F, Marchetti S, Rocchi S, Birling MC, Avril MF, Poulalhon N, Luc T, Hofman P, Lacour JP, Davidson I, Bressac-de Paillerets B, Ballotti R, Marine JC, Bertolotto C
Journal of the National Cancer Institute Apr 2017
Deregulated MITF sumoylation: A route to melanoma.Auteurs Ballotti R, Bertolotto C
Molecular & cellular oncology Jan 2017
FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells.Auteurs Bourseguin J, Bonet C, Renaud E, Pandiani C, Boncompagni M, Giuliano S, Pawlikowska P, Karmous-Benailly H, Ballotti R, Rosselli F, Bertolotto C
Scientific reports Nov 2016
ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.Auteurs Richard G, Dalle S, Monet MA, Ligier M, Boespflug A, Pommier RM, de la Fouchardière A, Perier-Muzet M, Depaepe L, Barnault R, Tondeur G, Ansieau S, Thomas E, Bertolotto C, Ballotti R, Mourah S, Battistella M, Lebbé C, Thomas L, Puisieux A, Caramel J
EMBO molecular medicine Oct 2016
Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.Auteurs Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, Botton T, Ronco C, Abbe P, Amdouni H, Passeron T, Hofman V, Mograbi B, Dabert-Gay AS, Debayle D, Alcor D, Rabhi N, Annicotte JS, Héliot L, Gonzalez-Pisfil M, Robert C, Moréra S, Vigouroux A, Gual P, Ali MMU, Bertolotto C, Hofman P, Ballotti R, Benhida R, Rocchi S
Cancer cell Juil 2016
Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.Auteurs Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P, , Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B
Nature Mar 2016